$32.52
-1.68-4.91%
Last update: Nov 6, 4:42 PM
Castle Biosciences Inc
CSTLNASDAQ
Castle Biosciences (CSTL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Castle Biosciences (CSTL) last issued guidance on November 5, 2026 for fiscal year 2026. The company guided revenue in the range of $385M - $395M for the period.
Compared to prior guidance, Castle Biosciences raised its revenue forecast from a prior range of $365M - $375M.
Castle Biosciences has issued 16 guidance updates between February 28, 2023 and November 5, 2026. During this period, the company raised its outlook 11 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.35 | $-0.41 | $-0.50 | $-0.24 |
| Actual | $-0.13 | $-0.07 | $-0.49 | $-0.08 |
| Surprise | +62.9% | +82.9% | +2.00% | +66.7% |
| Revenue | ||||
| Estimate | $92.7M | $86.6M | $79.7M | $80.3M |
| Actual | $102.9M | $103.5M | $83.7M | $87.0M |
| Surprise | +11.0% | +19.6% | +5.03% | +8.34% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.35 | $-0.39 | $-0.25 | $-0.15 |
| Revenue | ||||
| Consensus | $94.8M | $98.6M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.13 | $-0.35 | 62.9 % |
| Q2 | Jul 30, 2026 | $-0.07 | $-0.41 | 82.9 % |
| Q1 | May 6, 2026 | $-0.49 | $-0.50 | 2.00 % |
| Q4 | Feb 26, 2026 | $-0.08 | $-0.24 | 66.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $102.89M | $92.72M | 11.0 % |
| Q2 | Jul 30, 2026 | $103.55M | $86.56M | 19.6 % |
| Q1 | May 6, 2026 | $83.70M | $79.69M | 5.03 % |
| Q4 | Feb 26, 2026 | $87.01M | $80.31M | 8.34 % |
